NBB ... I have been amazed also at how this stock continues to fly under the radar.

Guessing it is a combination:

* Tightly held

* Not on a major U.S. market for exposure (pink sheets scares many)

* Relatively unknown company with zero sales or track record (not Merck/Pfizer/Lilley etc)

* History of shortfall

* New and unproven drug class in addition to unproven company/drug

* Shoestring "on the brink" financials

Personally, I think a well known BP horse hitching up to the RVX buggy changes everything, well at least allays most of the above and makes it appear to actually be going somewhere ... having the full attention of both the FDA and a BP, along with a large market will be some pretty writing on the wall.